Watson's generic Exelon makes market debut

MORRISTOWN, N.J. Watson Pharmaceuticals has launched a generic version of a drug used to treat dementia under a settlement agreement with Swiss drug maker Novartis, Watson said Thursday.

The generic drug maker announced the launch of rivastigmine tartrate capsules in the 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths.

The drug is a generic version of Novartis’ Exelon, used to treat dementia in patients with Alzheimer’s disease. Exelon had sales of $425 million during the 12-month period ended in April, according to IMS Health.

Login or Register to post a comment.